The US Health and Human Services agency isn’t ready to go all in on “pull” incentives to encourage the development of new antibiotics, the agency indicated in response to a new Government Accountability Office report.

“It is still unclear whether post-market financial incentives should necessarily be part of HHS’s forthcoming strategic framework to further incentivize the development of new treatments to combat antibiotic resistance,” Sarah Arbes, acting assistant secretary for legislation, wrote in response to a sweeping two-year audit of HHS’s work to address the antibiotic resistance crisis.

“Pull” incentives include new reimbursement schemes or other forms of post-market financial support… Read more »